{
    "organizations": [],
    "uuid": "d0bf9bd65a702e87b976a4f590e756f9c40314c3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-regeneron-says-fda-to-conduct-prio/brief-regeneron-says-fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-idUSASC09Y4T",
    "ord_in_thread": 0,
    "title": "BRIEF-Regeneron Says FDA To Conduct Priority Review Of Cemiplimab As A Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News April 30, 2018 / 6:19 AM / Updated 3 minutes ago BRIEF-Regeneron Says FDA To Conduct Priority Review Of Cemiplimab As A Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma Reuters Staff 1 Min Read\nApril 30 (Reuters) - Regeneron Pharmaceuticals Inc:\n* FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA\n* SAYS TARGET ACTION DATE FOR FDA DECISION IS OCTOBER 28, 2018. Source text for Eikon: Further company coverage:",
    "published": "2018-04-30T09:16:00.000+03:00",
    "crawled": "2018-04-30T09:23:54.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "april",
        "updated",
        "minute",
        "ago",
        "say",
        "fda",
        "conduct",
        "priority",
        "review",
        "cemiplimab",
        "potential",
        "treatment",
        "advanced",
        "cutaneous",
        "squamous",
        "cell",
        "carcinoma",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "regeneron",
        "pharmaceutical",
        "inc",
        "fda",
        "conduct",
        "priority",
        "review",
        "cemiplimab",
        "potential",
        "treatment",
        "advanced",
        "cutaneous",
        "squamous",
        "cell",
        "carcinoma",
        "say",
        "target",
        "action",
        "date",
        "fda",
        "decision",
        "october",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}